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Abstract
Purpose—The purpose of this study was to examine if patient demographic factors influenced 
self-reporting of medication side effects, difficulty with drop instillation and nonadherence to 
glaucoma therapy.
Methods—English-speaking adult glaucoma patients (n=279) from six ophthalmology clinics 
were enrolled. Patients’ medical visits were videotaped and patients were interviewed immediately 
afterwards by research assistants. The videotapes were transcribed verbatim and coded to identify 
patients who expressed problems with medication side effects, eye drop administration, and non-
adherence during the glaucoma office visits. Generalized estimating equations were performed to 
identify whether patient characteristics were associated with expression of problems with 
glaucoma medication and medication non-adherence during the office visit.
Results—Patients with lower health literacy were significantly less likely to express problems 
with side effects (OR (95%CI) = 0.47 (0.25, 0.88)) and eye drop administration (OR (95%CI) = 
0.26 (0.11, 0.63)) during the visit. Patients who reported eye drop administration and side effect 
problems during the interview were significantly more likely to express these problems to their 
ophthalmologists, (OR (95%CI) = 3.13 (1.82, 5.37)); (OR (95%CI) = 1.86 (1.12, 3.08)) 
respectively. Patients who expressed a problem with eye drop administration and with side effects 
were significantly more likely to express medication non-adherence to their ophthalmologist (OR 
(95%CI) = 2.89 (1.44, 5.80)); (OR (95%CI) = 2.03 (1.16, 3.54)). Patients who reported greater 
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than 80% medication adherence during the interview were significantly less likely to express non-
adherence to their ophthalmologist (OR (95%CI) = 0.22 (0.12, 0.40)).
Conclusions—Eye care providers should be aware that glaucoma patients with lower health 
literacy are less likely to express problems with side effects and eye drop administration. Providers 
should work with patients to assess medication-related problems in order to mitigate potential 
barriers to medication adherence since patients who expressed medication problems were also 
more likely to express non-adherence.
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Glaucoma is an incurable chronic eye disease that affects over 2 million people in the United 
States.1 As the U.S. population continues to age, glaucoma is projected to affect over 3 
million people by 2020.1 To prevent or delay the progression of glaucoma, intraocular 
pressure-lowering medication eye drops are typically prescribed for life-long use. These 
medications are effective in slowing the progression of glaucoma; however, their 
effectiveness depends on patient adherence to the prescribed medication regimen. Research 
has found medication adherence to be a significant problem in the glaucoma patient 
population.2–4 Barriers to glaucoma medication adherence include: medication side effects, 
difficulty with eye drop administration, low health literacy skills, depressive symptoms and 
complex medication regimens.5–9 In order for physicians to address these barriers to 
adherence, patients must express their specific problems and concerns during their medical 
encounters.
There is limited literature on the relationship between patient characteristics and expression 
of medication side effects to an eye care provider. In a prior study, patients who were using 
adjunctive therapy for glaucoma were surveyed to examine patient-reported problems and 
found that 60% of them expressed at least one problem with their medication.10 Difficulty 
with eye drop administration was the most commonly cited problem.10 Younger patients 
were more likely to report problems with side effects and females were more likely to report 
problems with eye drop administration.10
There have been additional studies investigating a similar relationship in other chronic 
disease states. Sleath et al. found that younger and non-Hispanic white patients were more 
likely to express a complaint about their antidepressant medications than older and Hispanic 
patients.11 The most commonly expressed complaints were medication side effects and lack 
of medication efficacy.11 In another study, investigators examined the extent of patient-
expressed complaints with their chronic disease medication regimens.12 The most 
commonly expressed complaints included: medication side effects, medication not working, 
medication expense, having to take the medication, and having to use generic rather than 
brand named medication.12 This study found that patients were significantly more likely to 
express complaints about their medication regimen to younger physicians, and physicians 
were more likely to change the patient’s medication regimen if a problem was expressed.12
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Similarly, there are few studies that examine the relationship between patient characteristics 
and an expression of medication non-adherence to an eye care provider. It is not clear what 
glaucoma patient characteristics are associated with an expression of non-adherence to an 
eye care provider. Sleath et al. found patients who expressed one or more complaints about 
their medication regimen to their physician were twice as likely to express an adherence 
problem as compared with patients who did not.13 Additionally, patients reporting difficulty 
with eye drop administration were more likely to report lower rates of adherence.13 Another 
study found that 14% of patients receiving adjunctive therapy for glaucoma reported 
problems with medication adherence.10 That study also found patients who reported 
medication problems were more likely to be non-adherent to their medications in the prior 
week.10
It is important for providers to understand which patient characteristics are associated with 
patient expression of medication problems and non-adherence so that they can collaborate 
with the patient to find a medication regimen, or alternative treatment plan (e.g., surgery) 
that mitigates the patient’s problems or concerns. In turn, this may help glaucoma patients 
become more adherent to their glaucoma medication.
To our knowledge, no one has assessed what specific glaucoma patient characteristics are 
associated with patient expression of medication problems or medication non-adherence 
during clinic visits. The purpose of the paper was to evaluate what patient characteristics 
lead patients to express: (1) medication problems, including difficulty with side effects and 
eye drop administration, and (2) problems with non-adherence to glaucoma medications.
METHODS
From 2009 to 2012, we recruited English-speaking adult glaucoma patients and 
ophthalmologists from six ophthalmology clinics located in four states. Four clinics were 
affiliated with academic ophthalmology departments and two were private offices. Provider 
consent was obtained. To see if provider race, age or gender would influence outcome 
variables, providers completed a short demographic questionnaire. Clinic staff referred 
eligible patients to a clinic-based research assistant. Patient consent was obtained after the 
study was explained. The patient’s medical visit was videotape-recorded and then 
transcribed verbatim with identifiers removed. Research assistants interviewed patients 
immediately after their medical visits and collected information on demographic 
characteristics and medication related problems. The medical visit transcripts were coded to 
identify statements where patients self-reported medication side effects, difficulty with drop 
instillation and nonadherence to glaucoma therapy.
The institutional review boards at the University of North Carolina at Chapel Hill, Duke 
University, Emory University, and the University of Utah approved this study. This study 
adhered to the tenets of the declaration of Helsinki.
Measurement
Patient Characteristics—Patient age was measured as a continuous variable. Patient 
gender was measured as a dichotomous variable. Self-reported patient race was measured as 
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a categorical variable (White, African American, Asian, Native American, and Hispanic) 
and then recoded into African American and non-African American since the majority of the 
patient sample (95.3%) was either African-American or White. The number of glaucoma 
medications was measured as a discrete variable, and then recoded as a dichotomous 
variable (one glaucoma medication versus two or more) since the majority of the patient 
sample (95.7%) was taking one or two glaucoma medications. The number of prescription 
medications other than glaucoma medications was measured as a discrete variable since the 
variable ranged from 0–22 prescription medications. Whether the patient had health 
insurance coverage and prescription drug insurance were measured dichotomously (yes/no). 
Self-reported problems with eye drop administration were measured as a categorical variable 
(none, a little, and a lot) and then recoded as a dichotomous variable (none versus a little/a 
lot). Self-reported problems with side effects of glaucoma medications were measured as a 
categorical variable (none, a little/a lot) and then recoded as a dichotomous variable (none 
versus a little or a lot).
Health literacy was evaluated using the Rapid Estimate of Adult Literacy in Medicine 
(REALM). REALM is a validated, fast-screening instrument designed to identify patients 
who have difficulty reading common medical and lay terms that are routinely used in patient 
education materials.14 Patient scores correspond to reading levels (score of 0–18 = third 
grade and below, 19–44 = fourth to sixth grade, 45–60 = seventh to eighth grade, 61–66 = 
ninth grade and above). REALM scores were dichotomized to “eighth grade or below” and 
“ninth grade and above” since patients reading below ninth grade have trouble reading most 
patient education materials.14
The Patient Health Questionnaire (PHQ-9) is a validated, multipurpose instrument designed 
to screen and assess the severity of depression.15,16 The PHQ-9 was measured as a 
continuous variable with values ranging from 0–27, with higher values indicating more 
severe depression. The PHQ-9 score is divided into the following categories with increasing 
severity: 0–4, 5–9, 10–14, 15–19, and 20 or greater.17 PHQ-9 scores of 5, 10, 15, and 20 
represent mild, moderate, moderately severe, and severe depression.17
Patient medication adherence was measured using a Visual Analog Scale (VAS), which asks 
the patient to draw a line through a 10 cm scale to indicate how much of the time they use 
all of their glaucoma medications exactly as directed during the past week. The scale ranges 
from 0 cm (none of the time) to 10 cm (all of the time). The VAS has strong validity and 
reliability and has been validated against prescription drug refill records.9,18–21 The VAS 
score was recoded into a dichotomous variable (less than 8.0 cm which is equivalent to less 
than 80% adherent versus 8.0 cm or greater which is 80% adherent or greater), which is 
supported by the glaucoma literature.22,23
Each videotape recording of the medical encounter was transcribed verbatim with identifiers 
removed. A detailed coding tool was developed over a one-year period with input from the 
communication experts and ophthalmologists on the study team. Using this coding tool, 
three coders denoted (yes/no) whether the patient expressed medication side effects, 
difficulty with drop administration, and nonadherence during their medical visit and 
recorded the content of what the patients said. Next, a single coder categorized the patient 
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statements into the following areas: (a) expresses a problem with eye drop administration, 
(b) expresses a problem with side effects of the glaucoma medications, and (c) expresses 
non-adherence to glaucoma medication regimen to their ophthalmologist.
Data Analysis
Descriptive analyses were performed using IBM SPSS Statistics version 21. The statistical 
significance level was set at p < 0.05. Descriptive statistics were calculated for the patient 
demographic variables. Generalized estimating equation (GEE) analyses were performed 
using SAS version 9.3 to examine whether patient age, gender, race, number of glaucoma 
medications, health literacy, depression, the number of prescription non-glaucoma 
medications, and self-reported medication problems (side effects and eye drop 
administration) were associated with whether the patient expressed problems with the side 
effects of glaucoma medications and whether the patient expressed problems with 
administering glaucoma medications during the office visit with their ophthalmologist. 
Additionally, GEE analysis was performed to examine whether patient age, gender, race, 
number of glaucoma medications, health literacy, depression, the number of prescription 
non-glaucoma medications, whether the patient expressed any problems with administering 
glaucoma medications, whether the patient expressed any problems with glaucoma 
medication side effects, and medical adherence were associated with the expression of 
medication non-adherence during the office visit with their ophthalmologist. Provider race, 
age and gender were excluded from the GEE models because they were not significantly 
associated with the outcome variables in bivariate analysis. All GEE models were clustered 
by provider.
RESULTS
Two hundred seventy-nine patients participated in the study. Table 1 illustrates the 
characteristics of study participants. One hundred sixty-five (59%) patients were female and 
99 (36%) were African American. Ninety-one (33%) patients were taking two or more 
glaucoma medications.
Less than half of patients (40.5%) reported problems with eye drop administration and 
13.3% reported problems with side effects of their glaucoma medications. The average 
medication adherence rate was 89% (range = 0–100%). Thirty-four (15%) patients reported 
being less than 80% adherent and 193 (69.2%) patients reported being more than 80% 
adherent.
Side Effect Problems
One hundred twenty-five (45%) patients expressed a problem related to medication side 
effects during their medical encounter with their ophthalmologist. Table 2 presents the GEE 
results predicting whether patient characteristics are associated with patients’ expression of 
problems relating to side effects. Patients with lower health literacy were significantly less 
likely to express a problem with glaucoma medications side effects (p = 0.018). Patients 
who reported a side effect problem during the post-medical visit interview to the research 
assistant were significantly more likely to have expressed a problem with side effects to 
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their ophthalmologist (p = 0.017). No other patient characteristics were significantly 
associated with whether a patient expressed a problem or concern with side effects of 
glaucoma medications.
Eye Drop Administration Problems
Twenty-six (9%) patients expressed a problem with eye drop administration during their 
office visit with their ophthalmologist. Table 2 presents the GEE results predicting whether 
patient characteristics influence patients’ expression of eye drop administration problems. 
Patients with lower health literacy were significantly less likely to express a problem with 
eye drop administration (p = 0.003). Patients who reported an eye drop administration 
problem during the post-medical visit interview with the research assistant were 
significantly more likely to express a problem with eye drop administration to their 
ophthalmologist (p < 0.0001). No other patient characteristics – gender, race, number of 
glaucoma medications, number of other non-glaucoma prescription medications, depression, 
and new or prevalent glaucoma medication user – were significantly associated with 
expression of problem with eye drop administration.
Expression of Non-Adherence
Sixty-two (22%) patients expressed glaucoma medication non-adherence to their 
ophthalmologist during their medical visit. Table 3 presents the results of the GEE analysis 
predicting whether patient characteristics are associated with the expression of non-
adherence to glaucoma medication regimens. Patients who had fewer non-glaucoma 
prescription medications (p = 0.001) and patients who had two or more glaucoma 
medications (p = 0.025) were significantly less likely to express non-adherence to their 
ophthalmologist. Patients who expressed at least one problem with eye drop administration 
(p < 0.003) and patients who expressed at least one problem with glaucoma medication side 
effects (p = 0.013) were significantly more likely to express a problem with medication 
adherence to their ophthalmologist. Patients who reported greater than or equal to 80% 
medication adherence were significantly less likely to express a problem with medication 
adherence to their ophthalmologist (p < 0.0001). No other patient characteristics were 
significantly associated with whether a patient expressed a problem with glaucoma 
medication non-adherence to their ophthalmologist.
DISCUSSION
This is the first study to investigate whether patient characteristics influence patient 
expression of medication problems to their eye care providers during ophthalmology office 
visits. Although only 13.3% of glaucoma patients reported a side effect problem during their 
interview with the research assistant, almost half of patients expressed a problem with 
glaucoma medication side effects to their ophthalmologist. Patients who reported problems 
with side effects to the research assistant were significantly more likely to express a problem 
with side effects to their ophthalmologist. Additionally, we found that patients with lower 
health literacy were less likely to express a problem with side effects of glaucoma 
medications. Patients with lower health literacy may have greater difficulty communicating 
with their physicians about their medications. Prior work has found health literacy to be a 
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barrier to patient-provider communication and medication adherence.24 Providers should 
consider using brief health literacy screening instruments, like the REALM, in their 
practices and spending more time assessing medication-related problems with patients who 
have lower health literacy.
In contrast to previous studies, we did not find that age or race were associated with patient 
expression of medication side effects.9,10 Providers should consider asking more open-ended 
questions regarding medication side effects so that patients know specifically that the 
provider would like them to communicate their concerns. Eye care providers can ask open-
ended questions such as “Some patients experience side effects when using glaucoma 
medications, what have you noticed?” or by asking targeted close-ended questions such as 
“Are you having any side effects, like red or itchy eyes from your glaucoma medications?” 
to engage their patients in a discussion whether the patient has been experiencing side 
effects. This study showed an association between patient expression of side effects and an 
expression of non-adherence. Since prior literature has found side effects to be a major 
barrier to medication adherence,9,25–27 eye care providers should be aware that patients 
expressing problems with side effects may also be struggling with medication adherence.
Less than 10% of patients expressed a problem with eye drop administration to their 
ophthalmologist compared to 40.5% who reported a problem during the post-medical visit 
interview with the research assistant. Prior research has found a significant relationship 
between poor eye drop technique and non-adherence.6,13,16,25,28,29 Since patients rarely 
expressed problems with eye drop administration, they may not recognize if they have poor 
eye drop technique or they may feel uncomfortable discussing their concerns with their 
ophthalmologist.6 Lower health literacy was significantly associated with being less likely to 
express problems with eye drop administration. Additionally, patients who self-reported eye 
drop administration problems were significantly more likely to express a problem with 
glaucoma medication administration to their ophthalmologist. We found that neither age nor 
gender were associated with whether patients expressed a problem with eye drop 
administration to their ophthalmologist, which contradicts the results of a prior study.11 
However, this may be the result of so few patients in this study expressing an eye drop 
administration problem to their ophthalmologist. Eye care providers can ask open-ended 
questions such as “What problems are you having when you administer or use your 
glaucoma eye drops?” or “Some patients have a hard time putting in their own eye drops, 
what issues do you have when you use your eye drops?” to initiate a discussion about 
administering eye drops.
One in five patients expressed medication non-adherence during their medical encounters 
compared to 12.2% that reported less than perfect adherence on the post-visit interview. This 
small percentage of patients expressing non-adherence to their ophthalmologists is 
concerning since prior research has shown adherence to be a significant problem in the 
glaucoma patient population.2,30,31 Furthermore, previous research has found that about 
one-half of individuals discontinue glaucoma medication therapy within six months of 
beginning it.2 In this study, patients who were using more non-glaucoma prescription 
medications were more likely to express non-adherence. Prior work has found that the more 
medications a patient is taking, the more problems the patient will have with medication 
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adherence.3,32 Interestingly, patients taking two or more glaucoma medications were 
significantly less likely to express non-adherence to their ophthalmologist.
Patients who reported their glaucoma medication adherence was greater than 80% were 
significantly less likely to express non-adherence to their ophthalmologist. This may be due, 
in part, to patients over-reporting their medication adherence.21 Eye care providers may 
want to take the time to discuss strategies to improve medication adherence to patients 
taking more than one prescription medication, and to problem-solve any potential barriers to 
medication adherence. Providers could initiate conversations about adherence strategies by 
asking open-ended questions such as, “Some patients have a hard time remembering to take 
their glaucoma medications, tell me how you remember to take your medications?” 
Additionally, providers may want to provide suggestions to help patients incorporate 
medication taking into their daily routine, by stating, “Some patients keep their glaucoma 
medications next to their toothbrush, and use their glaucoma medication after they brush 
their teeth.”
This study has several limitations and therefore results should be interpreted with caution. 
The provider sample size is relatively small with 15 ophthalmologists. Also, patients and 
providers knew the visit was being recorded but they were not aware of the study 
hypotheses. Additionally, we cannot estimate the effect of selection bias since the clinic staff 
did not track the number or characteristics of patients they approached who refused to 
participate in the study.
CONCLUSIONS
This study provides important information on the relationship between glaucoma patient 
characteristics and expression of side effects, eye drop administration difficulties, and 
medication non-adherence to ophthalmologists during medical visits. Specifically, we found 
that patients with lower health literacy are less likely to express medication related problems 
and patients that express medication problems often express non-adherence. This study 
showed an association between patient expression of side effects and an expression of non-
adherence. In order to improve medication adherence, providers should work with patients 
to assess their unique medication-related problems and develop strategies to overcome these 
problems.
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Table 1
Characteristics of Glaucoma Patients (N=279).
Percent (N)
Gender
 Male 40.9 (114)
 Female 59.1 (165)
Race
 African American 35.5 (99)
 Non-African American 64.2 (179)
Number of Glaucoma Medications Used
 One 67.0 (187)
 Two or more 32.6 (91)
REALM
 Eighth grade or lower 14.0 (39)
 Ninth grade or higher 84.2 (235)
Health Insurance Coverage
 Patient has health insurance 97.5 (272)
 Patient does not have health insurance 2.5 (7)
Prescription Drug Insurance
 Patient has prescription drug insurance 94.3 (263)
 Patient does not have prescription drug insurance 5.7 (16)
Patient Self-Reported Administration Problems
 None 59.5 (166)
 A Little or a Lot 40.5 (113)
Patient Self-Reported Side Effect Problems
 None 86.7 (242)
 A Little or a Lot 13.3 (37)
Patient Self-Reported Medication Adherence
 80% or greater on VAS 85.0 (193)
 Less than 80% on VAS 15.0 (34)
Range; Mean (Standard Deviation)
Age 21–93; 65.8 (12.8)
PHQ-9 Score 0–18; 2.18 (3.3)
Number of Prescription Medications in Addition to Glaucoma Medications 0–22; 3.9 (3.5)
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Table 2
Generalized estimating equation results predicting whether patients express a problem with side effects or 
difficulties administering their glaucoma medications to their ophthalmologist (N=273).
Independent Variables
Patient expressed concern/
problem with side effects of 
glaucoma medications
OR (95% CI)
Patient expressed concern/problem 
with the administration of glaucoma 
medications
OR (95% CI)
Patient Age 1.02 (1.00, 1.04) 1.03 (0.99, 1.07)
Patient Gender 1.02 (0.55, 1.90) 0.80 (0.41, 1.55)
Patient Race, African American 0.79 (0.44, 1.41) 1.15 (0.45, 2.95)
Number of glaucoma medications 1.24 (0.73, 2.09) 0.35 (0.12, 1.05)
Health Literacy, reads at an eighth-grade level or below 0.47 (0.25, 0.88)* 0.26 (0.11, 0.63)**
Depression, PHQ-9 1.01 (0.91, 1.11) 1.05 (0.98, 1.13)
Number of other prescription medications 1.00 (0.93, 1.08) 1.04 (0.92, 1.19)
Patient self-reports side effects of glaucoma medications 1.86 (1.12, 3.08)* -
Patient self-reports problems with administration of 
glaucoma drops
- 3.13 (1.82, 5.37)***
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Table 3
Generalized estimating equation results predicting whether patients express an adherence problem to 
glaucoma medications to their ophthalmologist (N=273).
Independent Variables
Patient Expressed Concern/Problem with Non-adherence to 
Glaucoma Medication
OR (95% CI)
Age 1.00 (0.98, 1.02)
Gender 0.80 (0.47, 1.38)
Race, African American 0.61 (0.30, 1.22)
Number of glaucoma medications, 2 or more medications 0.52 (0.29, 0.92)*
Health literacy, reads at an 8th-grade level or below 1.73 (0.61, 4.90)
Depression, PHQ-9 0.99 (0.91, 1.08)
Number of non-glaucoma prescription medications 0.87 (0.81, 0.94)***
Patient expresses a problem with administration of glaucoma medication 2.89 (1.44, 5.80)**
Patient expresses a problem with side effects of glaucoma medication 2.03 (1.16, 3.54)*
Visual Analog Scale, ≥ 80% 0.22 (0.12, 0.40)***
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